Aurora Cannabis (ACB) Income from Non-Controlling Interests (2018 - 2026)
Aurora Cannabis (ACB) posted quarterly Income from Non-Controlling Interests of $7.3 million for Q1 2026, up 435.49% year-on-year from $1.4 million in Q1 2025, and up 371.88% on a QoQ basis from -$2.7 million in Q4 2025.
Aurora Cannabis (ACB) Income from Non-Controlling Interests (2018 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Income from Non-Controlling Interests for 8 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 435.49% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84057.7 (up 115.06% YoY) and the FY2025 annual result came in at -$487005.4, up 82.47% from the prior year.
- Income from Non-Controlling Interests grew to $7.3 million in Q1 2026 per ACB's latest filing, from -$2.7 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for ACB reached as high as $7.3 million in Q1 2026 and fell as low as -$3.4 million in Q2 2025.
- A 5-year average of -$260930.5 and a median of -$677341.4 in 2024 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests slumped 1044.0% — and 2026, when it soared 435.49%.
- Year by year, Income from Non-Controlling Interests stood at -$1.5 million in 2022, then jumped by 48.58% to -$781545.8 in 2023, then surged by 70.14% to -$233366.8 in 2024, then sank by 1044.0% to -$2.7 million in 2025, then surged by 371.88% to $7.3 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $7.3 million, -$2.7 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.06 Bn | 20.90 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.43 Bn | 18.62 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.81 Bn | 16.49 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | - |
| 10 | Aurora Cannabis | 155.11 Mn | 69.87 Mn | 21.72 Mn | 7.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.26 Mn |
| Dec 31, 2025 | -2.67 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | -233,366.82 |
| Sep 30, 2024 | -677,341.35 |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | 264,934.42 |
| Dec 31, 2023 | -781,545.80 |
| Sep 30, 2023 | -1.20 Mn |
| Dec 31, 2022 | -1.52 Mn |
| Sep 30, 2022 | -216,989.19 |
| Jun 30, 2022 | 8,627.75 |
| Mar 31, 2022 | 1,578.95 |
| Dec 31, 2021 | -291,154.34 |
| Sep 30, 2020 | -1.10 Mn |
| Sep 30, 2018 | -979,927.44 |